Novartis Q1: Priority Brands Surge but Generic Erosion and R&D Spend Weigh; FY 2026 Guidance Reaffirmed

What happened

Novartis reported Q1 2026 net sales down 5% constant currency (-1% USD) as strong growth from priority brands like Kisqali (+55%), Pluvicto (+70%), Kesimpta (+26%), Scemblix (+79%), and Leqvio (+69%) was more than offset by US generic erosion, particularly from Entresto. Core operating income declined 14% constant currency due to lower net sales and higher R&D investment, pushing the core operating margin to 37.3% from 39.3% a year ago, with core EPS falling 15% to $1.99. Despite the headline decline, the company delivered several innovation milestones including a positive CHMP opinion for remibrutinib in CSU, FDA Breakthrough Therapy for ianalumab in Sjögren's disease, and completed the Avidity acquisition. Management reaffirmed full-year 2026 guidance for low single-digit net sales growth and low single-digit core operating income decline, signaling confidence that the priority brand momentum will continue to offset generics. The results are in line with the DeepValue report's base case scenario, which sees steady priority brand uptake balanced by Entresto decline, but the margin pressure is more acute than expected, supporting the report's conviction at 4/10 and potential sell rating.

Implication

While the priority brand growth validates management's pipeline strategy, the 14% core operating income decline and margin slip to 37.3% underscore the risks of concentrated reliance on a handful of assets and the cost of aggressive M&A (like Avidity). The reaffirmed guidance may provide a floor, but the stock at ~19.5x trailing earnings already prices in a smooth transition, leaving little room for error. Over the next 6-18 months, investors should watch for sustained margin improvement toward the 38-39% range and evidence that Entresto erosion is decelerating. The DeepValue report's bear case of $120 becomes more probable if generic uptake accelerates or priority brands show signs of slowing. For now, the risk/reward skews negative, and we advise trimming positions on any strength above $145.

Thesis delta

The Q1 results do not materially change the thesis but sharpen its focus. The 14% core operating income decline is steeper than the gradual margin dilution that was expected, indicating that the headwinds from generic erosion and investment spending are hitting faster. The reaffirmed guidance suggests management expects an inflection, but the market will demand concrete evidence of earnings stability before re-rating.